BMS-906024

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[(3S)-3-[[4-(4-cyanophenoxy)phenyl]methyl]piperidin-1-yl]-N-[(2S)-1-[(3,5-difluorophenyl)methyl]pyrrolidin-2-yl]-2-oxoacetamide | image = BMS-906024.svg | width = 200 | alt = Chemical structure of BMS-906024 }}

BMS-906024 is an experimental drug that acts as a gamma-secretase inhibitor. It is being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

BMS-906024 functions by inhibiting the activity of gamma-secretase, an enzyme complex that plays a crucial role in the Notch signaling pathway. The Notch signaling pathway is involved in cell differentiation, proliferation, and apoptosis. By inhibiting gamma-secretase, BMS-906024 disrupts this pathway, which can lead to the suppression of tumor growth and proliferation in certain cancers.

Clinical Development

BMS-906024 is currently undergoing clinical trials to evaluate its efficacy and safety in treating different types of cancer. The drug has shown promise in preclinical studies, particularly in cancers that are dependent on the Notch signaling pathway for growth and survival.

Potential Applications

The primary focus of BMS-906024's development is in oncology. It is being tested in various solid tumors and hematological malignancies. The drug's ability to target the Notch signaling pathway makes it a candidate for treating cancers that have limited treatment options.

Challenges and Considerations

While BMS-906024 shows potential, there are challenges associated with its development. The inhibition of gamma-secretase can lead to off-target effects, as this enzyme is involved in the processing of multiple substrates, including the amyloid precursor protein (APP). This can potentially lead to adverse effects similar to those seen in Alzheimer's disease. Therefore, careful monitoring and management of side effects are crucial during clinical trials.

Related Pages

• Gamma-secretase
• Notch signaling pathway
• Cancer treatment
• Experimental cancer drugs